Pfizer Inc. (NYSE:PFE) Stock Has Consensus Price Target of $28.39

Pfizer Inc. (NYSE:PFE – Get Free Report) has earned an average rating of “Hold” from the twenty-one analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $28.39.

PFE has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th.

Get Our Latest Stock Analysis on Pfizer

Pfizer Stock Up 0.9%

PFE opened at $28.68 on Friday. Pfizer has a 12 month low of $23.61 and a 12 month high of $29.21. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $27.05 and its 200-day moving average price is $26.43. The company has a market cap of $163.44 billion, a P/E ratio of 37.73, a P/E/G ratio of 1.93 and a beta of 0.34.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer will post 2.98 EPS for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is emphasizing pipeline programs that could qualify for FDA Breakthrough Therapy or orphan-drug designations. Faster reviews, regulatory incentives and expanding rare-disease markets could shorten the path to revenue and improve the company’s long-term growth outlook. What Could Pfizer Unlock From Faster FDA Reviews and Orphan Drug Growth?
• Positive Sentiment: Analysts are highlighting Pfizer’s newer-drug pipeline and cost-cutting plans as potential offsets to declining pandemic-related revenue and upcoming patent pressures. Successful execution could support earnings stabilization and future growth. Pfizer: Poised for Gains With a New Drug Pipeline and Cost-Cutting Plans
• Positive Sentiment: The FDA approved the 2026–2027 COMIRNATY XFG COVID-19 vaccine formula developed by Pfizer and BioNTech. Its focus on adults 65 and older and higher-risk younger patients could provide a seasonal revenue opportunity, although demand is likely more limited than during the pandemic. Could a New Vaccine Formula XFG Give Pfizer and BioNTech a Post-Pandemic Revenue Boost?
• Positive Sentiment: Pfizer completed a Phase 3 Japanese study of its RSVpreF vaccine, expanding the potential adult RSV market if regulatory filings and approval follow. Pfizer’s Japanese RSV Vaccine Study Wraps Up
• Neutral Sentiment: Pfizer has returned substantial cash to shareholders—about $49 billion according to one analysis—but dividends alone have not prevented long-term capital losses. The article underscores that future performance depends on earnings growth, not yield alone. Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
• Neutral Sentiment: Comparisons with AbbVie and other large pharmaceutical companies emphasize that Pfizer’s outlook will depend on pipeline productivity, acquisitions, patent exposure and its ability to replace lost pandemic sales. Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Pfizer during the fourth quarter valued at approximately $1,830,986,000. Bank of America Corp DE bought a new stake in Pfizer in the second quarter valued at $1,049,602,000. BlackRock Inc. increased its position in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. Bank of New York Mellon Corp raised its holdings in Pfizer by 38.9% in the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares in the last quarter. Finally, Nykredit A S bought a new position in Pfizer in the 2nd quarter worth $205,774,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

Featured Stories

• Five stocks we like better than Pfizer
• 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
• SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
• These 3 Overlooked Stocks Have Big Money Behind Them
• Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally